Edition:
United Kingdom

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

9.44USD
18 Apr 2019
Change (% chg)

$-0.40 (-4.07%)
Prev Close
$9.84
Open
$9.84
Day's High
$9.88
Day's Low
$9.30
Volume
104,292
Avg. Vol
70,528
52-wk High
$20.97
52-wk Low
$9.30

Aldrich, Richard 

Mr. Richard H. Aldrich is an Independent Chairman of the Board, Co-Founder of Concert Pharmaceuticals Inc. Mr. Aldrich is the Chairman of the Board, Co-Founder of Concert Pharmaceuticals Inc since May 2006. Mr. Aldrich is a Founder and has been Partner of Longwood Fund, a venture capital firm, since December 2010. Mr. Aldrich founded RA Capital Management LLC, a hedge fund, in 2004 and served as a Managing Member from 2004 to 2008 and as a Co-Founding Member from 2008 until 2011. Mr. Aldrich has co-founded several biotechnology companies including Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline in 2008, and Alnara Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2011. He has also held management positions at Vertex, where he was a co-founding employee, and Biogen Corporation (now Biogen Idec Inc., a biotechnology company). Mr. Aldrich co-founded and serves on the board of directors of Verastem, Inc., a public biopharmaceutical company and also serves on the boards of directors of OvaScience, Inc., a public life sciences company of which he serves as chairman of the board, and PTC Therapeutics, Inc., a public biopharmaceutical company. Mr. Aldrich received his undergraduate degree from Boston College, and an M.B.A. from the Amos Tuck School at Dartmouth College. We believe Mr. Aldrich’s broad-based experience in business, including his leadership and board experience at life science companies, and his familiarity with our business as a co-founder of our company allows him to be a key contributor to our board of directors.

Basic Compensation

Total Annual Compensation, USD 77,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 90,720
Fiscal Year Total, USD 167,720

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

167,720

Roger Tung

3,430,850

Marc Becker

--

Nancy Stuart

1,947,300

Lynette Herscha

--

James Cassella,

1,960,240
As Of  31 Dec 2017